The Gene Scene: SMAD3

 

6a4278f1584fa508874845.jpg

Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early. Here, we focus on the condition that led to the gene’s inclusion on the list, providing clear, relevant information that supports your clinic. To subscribe to the Gene Scene, contact your local GSL or send a request to info@ambrygen.com

To access the Gene Scene archives, visit our blog

6a4278f1593be546982939.png

Clinical Phenotype Summary: 

The SMAD3 gene (NM_005902.3), which contains 9 coding exons and is located on chromosome 15q22.33, encodes the mothers against decapentaplegic homolog 3 protein. Pathogenic variants in this gene are known to cause SMAD3-related Loeys-Dietz syndrome (LDS), which is inherited in an autosomal dominant fashion.

SMAD3-related Loeys-Dietz syndrome is characterized by:

●       Early onset osteoarthritis and osteochondritis dissecans

●       Aortic aneurysm and/or dissection with increased tortuosity of arterial vessels

●       Cutaneous findings, including translucent velvety skin, striae, and varices

●       Pes planus, scoliosis, and pectus deformity,

●       Craniofacial dysmorphism, including craniosynostosis, malar hypoplasia, bifid uvula or cleft palate, and hypertelorism.

Loss of function has been reported as the mechanism of disease for SMAD3-related LDS.

Unique Considerations: 

Individuals with SMAD3-related disease show a phenotypic spectrum with intra- and interfamilial variability and reduced penetrance.

Clinical Resources: 

Understanding Your Positive Genetic Test Result for Thoracic Aortic Aneurysms/Dissections (TAAD) or Related Conditions

Understanding Your VUS Genetic Test Result for Thoracic Aortic Aneurysms/Dissections (TAAD) or Related Conditions

Genetic Testing for Inherited Cardiovascular Disease Reference Guide

Understanding your Secondary Findings Result

Ambry Knows Genes: 

Peer-Reviewed Publications:

●       Smad3 promotes adverse cardiovascular remodeling and dysfunction in doxorubicin-treated hearts (Dec 2022)

Scientific Posters:

●       Family Matters: How Segregation Studies Reclassify Variants in Thoracic Aortic Aneurysm and Dissection Multigene Panels (ACMG 2016)

●       A retrospective analysis of multigene panel testing for Marfan syndrome, aneurysm, and related disorders: Diagnostic yield and cardiac phenotypic spectrum (ACMG 2015)

EducateNext Webinars: 

●       ACMG Secondary Findings Cardiology: Getting to the Heart of the Matter with Kelly Radtke, PhD (September 2024)

To read more about Ambry’s research, visit the ‘Our Research’ dropdown on our website https://www.ambrygen.com/science.  

Citations: 

●       van de Laar IM et al. J Med Genet, 2012 Jan;49:47-57 PMID: 22167769

●       Camerota L et al. Genes (Basel), 2019 Sep 28;10(10):764 PMID: 31569402

●       Gouda P et al. Int J Cardiol, 2022 Sep;362:158-167 PMID: 35662564

Ambry Genetics Gene-Disease Validity Scheme


Each week, we explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early. 

To learn more about the ACMG Secondary Findings list, click here

To read all previous Gene Scene emails, click here

Find Answers & Improve Patient Care

Ambry is committed to delivering the most accurate genetic test results possible. Learn more about our products today.

Love this article?

Get stories just like it, delivered right to your inbox.



Author

DISCLAIMER: THIS BLOG DOES NOT PROVIDE MEDICAL ADVICE

The information, including but not limited to, text, graphics, images and other material contained on this blog are for informational purposes only. The purpose of this blog is to promote broad understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this blog. Ambry Genetics Corporation does not recommend or endorse any specific tests, physicians, products, procedures, opinions or other information that may be mentioned on this blog. Reliance on any information appearing on this blog is solely at your own risk.

Subscribe

Subscribe to our blog for updates, sent out every month.

Recent Posts

Post Image

The Gene Scene: SMAD3

  • July 7, 2026
Post Image

The Gene Scene: POLE

  • June 30, 2026
Post Image

The Gene Scene: FLNC

  • June 23, 2026